Zydus Wellness

True North's arm Threpsi sells 2.6% stake in Zydus Wellness for Rs 374 cr

Private equity firm True North's arm Threpsi Care LLP on Tuesday divested a 2.6 per cent stake in Zydus Wellness for Rs 374 crore through an open market transaction, while Quant Mutual Fund picked up the stake in the consumer wellness company. According to the block deal data available on the National Stock Exchange (NSE), Threpsi Care LLP sold 17 lakh shares, amounting to a 2.67 per cent stake in Ahmedabad-based Zydus Wellness. The shares were disposed of at an average price of Rs 2,201.40 apiece, taking the transaction value to Rs 374.24 crore. After the share sale, Mumbai-based True North's stake in Zydus Wellness has reduced to 7.45 per cent from 10.12 per cent. These shares were acquired by Quant Mutual Fund at the same price. Shares of Zydus Wellness fell 0.16 per cent to close at Rs 2,220 per piece on the NSE. In December last year, True North through its arm Threpsi Care LLP divested a 1.23 per cent stake in Zydus Wellness for Rs 127 crore.

Zydus Wellness Q1 profit surges 33.78% amidst strong brand performance

The company's flagship brands, Glucon-D, Nycil, Everyuth Peel-off, and Scrub, continued to dominate their respective categories

Zydus Wellness stock jumps 5%; hits 2-year high on hopes of demand recovery

The management sees encouraging signs of industry recovery, with inflation stabilising and margins poised for improvement.

Zydus Wellness Q4 profit up 3.4%, driven by strong brand performance

For the full year of FY24, the company posted a 14 per cent Y-o-Y decline in PAT and the revenue grew by 3.2 per cent reaching Rs 266.9 crore and Rs 2,327.8 crore respectively

Zydus Wellness Q4: Net profit up 3.44% to Rs 150 cr, revenue at 782 cr

Zydus Wellness Ltd on Tuesday reported a 3.44 per cent rise in consolidated net profit at Rs 150.3 crore in the fourth quarter ended March 31, 2024. The company had posted a consolidated net profit of Rs 145.3 crore in the same quarter of the previous fiscal, Zydus Wellness said in a regulatory filing. Consolidated total revenue from operations in the quarter under review stood at Rs 782.6 crore, as against Rs 713 crore in the corresponding period a year ago, it said. Total expenses were higher at Rs 632.2 crore in the fourth quarter of financial year 2023-24, as compared to Rs 580.2 crore in the year-ago period. For the fiscal ended March 31, 2024 consolidated net profit was at Rs 266.9 crore, as against Rs 310.4 crore in the previous fiscal, the company said. In FY24, consolidated total revenue from operations stood at Rs 2,327.8 crore, as compared to Rs 2,254.8 crore in FY23. The board of directors at their meeting held on May 14, 2024 recommended a final dividend Rs 5 per equ

Zydus Group to invest Rs 5,000 cr across various sectors in Gujarat: Patel

Zydus Group on Friday announced plans to invest Rs 5,000 crore in Gujarat in various sectors, including new generation biotechnology products and hospitals, its Chairman Pankaj Patel said. Speaking at the 10th Vibrant Gujarat Global Summit here, Patel said his group has signed Memoranda of Understanding (MoUs) with the state for the investments. "We have signed MoUs of over Rs 5,000 crore. We'll be investing into next generation biotechnology products, new medical device initiatives and hospitals for the healthcare sector," he said. Patel said he has been attending the biennial summit since its inception and thanked Prime Minister Narendra Modi and Union Home Minister Amit Shah for helping businesses when it needs it the most. He said business needs leadership with a vision and the one that pushes it to think bigger, which is offered in Gujarat. Earlier, Nayara Energy's head of refinery Prasad Panicker said the company will be expanding its refinery at Vadinar and also upping its

True North's Threpsi Care LLP sells stake in Zydus Wellness worth Rs 127 cr

Private equity firm True North's arm Threpsi Care LLP on Thursday divested a 1.23 per cent stake in Zydus Wellness for Rs 127 crore through an open market transaction. Zydus Family Trust and SBI Mutual Fund were the buyers of Zydus Wellness shares. Threpsi Care LLP sold 7.80 lakh shares, amounting to a 1.23 per cent stake in Zydus Wellness, as per the block deal data available with the National Stock Exchange (NSE). The shares were offloaded at an average price of Rs 1,632 apiece, taking the deal size to Rs 127.30 crore. After the latest transaction, Threpsi Care LLP's shareholding has declined to 10.12 per cent from 11.35 per cent stake (at the end of September quarter) in the company. The scrip of Zydus Wellness gained 0.43 per cent to close at Rs 1,641 per piece on the NSE. In a separate deal on the NSE, ICICI Prudential Mutual Fund and SBI Mutual Fund offloaded more than 56.25 lakh shares of Indiabulls Housing Finance for Rs 123 crore through open market transactions. ICICI

Zydus Wellness Q1 results: Net profit falls 19.41% YoY to Rs 11,040 cr

Zydus Wellness' revenue from operations fell nearly 0.89% YoY to Rs 69,920 crore from Rs 69,300 crore last year

Delhi HC restrains Cipla from using Gluco-C or Gluco-D trademarks

Zydus argued that Cipla started branding its Glucose product under Gluco C ++ and Gluco D ++, in order to create confusion in the minds of customers

SC seeks response of firm Delhi marketing on plea by Zydus against HC order

The Supreme Court on Monday sought the response of a firm to a plea filed by consumer goods company Zydus Wellness challenging an order of the Delhi high court which held that it cannot use the brand name "SugarLite" for its products. A vacation bench of Justices J K Maheshwari and P S Narasimha issued notice to the firm named Delhi Marketing and sought its reply within three weeks. The top court was hearing an appeal filed by Zydus Wellness against the May 12 order of the high court which restrained it from using the brand name "SugarLite" as Delhi Marketing held the rights to use the brand name "SUGARLITE". The firm alleged that Zydus was using a deceptively similar trademark to confuse the customers and sought directions to restrain the company that manufactures nutrition and skin care products from using the SugarLite' brand name. Initially, Delhi Marketing had moved trial court in 2020 seeking permanent injunction for using the trademark SugarLite or any other identical or ...

India Inc in a wait-and-watch mode on impact of Rs 2,000 note withdrawal

Real estate sector may face the brunt; CEOs from other sectors hopeful of business as usual

Zydus Wellness net profit rise 9% YoY to Rs 145 crore in Jan-Mar quarter

Zydus Wellness Ltd on Wednesday reported a 9 per cent rise in consolidated net profit at Rs 145.33 crore in the fourth quarter ended March 31, 2023. The company had posted a consolidated net profit of Rs 133.3 crore in the year-ago period, Zydus Wellness said in a regulatory filing. Consolidated total revenue from operations stood at Rs 712.98 crore during the quarter under review as compared to Rs 639.78 crore in the year-ago period, it added. Total expenses during the quarter stood at Rs 580.23 crore, up from Rs 510.34 crore in the year-ago period. For the fiscal ended March 31, 2023 consolidated net profit was at Rs 310.37 crore as compared to Rs 308.87 crore in the previous year. For FY23 consolidated total revenue from operations was at Rs 2,254.79 crore as against Rs 2,009.1 crore in FY22, the company said. Zydus Wellness said five of its brands -- Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil -- maintained their leadership positions in their respective

Zydus Wellness Q4 results: Net profit up 9.02%, final dividend announced

The revenue from operations rose 11.44 per cent to Rs 712.98 crore in the quarter

Flu season starts, but demand for cough-cold meds remains weak

Impact in US among the worst in the past 10 years

Mehul Kothari recommends these 2 stocks on 'Symmetrical Triangle' breakout

According to the technical analyst from Anand Rathi, Godfreh Phillips can jump to Rs 1,320, while Zydus Wellness can be bought for a target of Rs 1,860.

Zydus Wellness net profit rises 4.75% in second qtr to Rs 137.01 cr

Zydus Wellness reported a 4.75 per cent rise in consolidated net profit to Rs 137.01 crore in the first quarter ended June 30, impacted by higher expenses and a one-time outgo for plant closure

Zydus Lifesciences gets 3 observations from USFDA for Vadodara plant

Zydus Lifesciences on Thursday said the US health regulator has issued three observations after inspecting its Jarod (Vadodara) based manufacturing facility. The US Food and Drug Administration (USFDA) inspected the injectable facility from February 24 to March 10, 2022. The inspection closed with three observations, the drug firm said in a regulatory filing. "We are confident of addressing and resolving the issues to the satisfaction of USFDA. We remain committed to building a quality culture across our entire manufacturing network, and are committed to remain compliant with high standards of good manufacturing practices across our network," Zydus Lifesciences stated. As per the US health regulator, an FDA Form 483 (observation) is issued to a firm's management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of Food Drug and Cosmetic (FD&C) Act and related Act.

Zydus Wellness Q3 net profit jumps over 1,200% YoY to Rs 23 crore

The company reported consolidated net sales of Rs 384.9 crore, a growth of 2.3%; Five key brands maintained leadership positions in respective categories

ABT enters wellness segment with flavoured drink under 'Mirakle' brand

Mirakle is more effective than oral vitamin C capsules and the absorption rate of nutrients in the drink is 98 per cent

Zydus Wellness expects to continue growth momentum on back of new launches

FMCG firm Zydus Wellness is expecting to continue its growth momentum gathered post easing of lockdown and grow the business on the back of new launches